The UK Government is investing £100 million to accelerate the use of AI in life sciences and healthcare under a new mission.
UK Prime Minister Rishi Sunak announced the AI Life Sciences Accelerator Mission in his speech last week.
The new initiative will capitalise on the UK's unique strengths in securing "health data and cutting-edge AI."
It will also help to identify those at risk of "dementia" and will ensure that patients participate in the trials at the right time to develop new treatments
effectively.
Henceforth, it will provide us with better data on how well new therapies work.
Sunak said: "AI can help us solve some of the greatest social challenges of our time. AI could help find novel dementia treatments or develop vaccines for cancer."
The World Health Organization called for caution on Tuesday (May 16) in using artificial intelligence for public healthcare, saying data used by AI to reach
decisions could be biased or misused.
The WHO said it was enthusiastic about the potential of AI but had concerns over how it will be used to improve access to health information, as a decision-support
tool and to improve diagnostic care.
The WHO said in a statement the data used to train AI may be biased and generate misleading or inaccurate information and the models can be misused to generate
disinformation.
It was "imperative" to assess the risks of using generated large language model tools (LLMs), like ChatGPT, to protect and promote human wellbeing and protect public
health, the U.N. health body said.
NHS England is rolling out a range of tech and data solutions, including an artificial intelligence (AI) system, across the health service to tackle winter
pressures.
The AI system will be used to identify patients at risk of hospital admission so community NHS teams can get to them first and reduce pressures on A&E departments.
On a trial basis, four GP practices in Somerset have started using the innovative technology which can highlight registered patients with complex health needs.
Health coaches, nurses, or GPs will then reach out to the people most at risk, and provide them with a range of preventive care such as monitoring, food parcels,
cleaning, shopping, as well as escalating care to specialist doctors.
Reacting to recommendations from a UK-first independent review, the Department of Health and Social Care (DHSC) has outlined action to tackle potential
bias in the design and use of medical devices.
Professor Dame Margaret Whitehead, professor of public health at the University of Liverpool, was appointed to lead the review, which focused on three
areas - optical devices such as pulse oximeters, AI-enabled devices, and polygenic risk scores (PRS) in genomics.
The DHSC commissioned the medical devices review after concerns were raised that pulse oximeters - widely used during the COVID-19 pandemic to monitor blood
oxygen levels - were not as accurate for patients with darker skin tones. There were worries that this could cause delays in treatment if dangerously low oxygen
levels in such patients were missed.
However, no evidence was found from NHS studies indicating that this differing performance had an impact on patient care.
Accepting the report's conclusions, the DHSC has committed to several actions, such as ensuring the safe use of pulse oximeter devices across a range of skin
tones within the NHS and eliminating racial bias from data sets employed in clinical studies.